Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Wilson Disease - Overview
Wilson Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Wilson Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Wilson Disease - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Aligen Therapeutics SL
Deep Genomics Inc
DepYmed Inc
Generation Bio Co
GMP-Orphan SA
Krisani Bio Sciences Pvt Ltd
LambdaGen Therapeutics
Nobelpharma Co Ltd
Ultragenyx Pharmaceutical Inc
Vivet Therapeutics SAS
Wilson Disease - Drug Profiles
CM-1186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DG-12P1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPM-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Wilson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ATP7B for Wilson Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBHD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methanobactin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tiomolibdate choline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trientine tetrahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UX-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zinc acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Wilson Disease - Dormant Projects
Wilson Disease - Product Development Milestones
Featured News & Press Releases
Apr 23, 2019: Vivet Therapeutics to present on its wilson disease drug candidate VTX-801 at 2019 American Society of Gene and Cell Therapy Annual Meeting
Jun 27, 2018: Progress toward improved Wilson’s disease drug
Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology
Apr 12, 2018: Promising prelimiry long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
Mar 28, 2018: Prelimiry Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting
Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease
Dec 14, 2017: WTX101 Granted Fast Track Desigtion by the U.S. FDA for the Treatment of Wilson Disease
Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease
Oct 20, 2017: Promising Prelimiry Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting
Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology
Oct 01, 2017: Promising Prelimiry Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting
Sep 26, 2017: Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Desigtion
Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting
Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting
Apr 24, 2017: Wilson Therapeutics presented positive fil Phase 2 data for WTX101 at EASL Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Wilson Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Wilson Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Wilson Disease - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
Wilson Disease - Pipeline by Aligen Therapeutics SL, H1 2020
Wilson Disease - Pipeline by Deep Genomics Inc, H1 2020
Wilson Disease - Pipeline by DepYmed Inc, H1 2020
Wilson Disease - Pipeline by Generation Bio Co, H1 2020
Wilson Disease - Pipeline by GMP-Orphan SA, H1 2020
Wilson Disease - Pipeline by Krisani Bio Sciences Pvt Ltd, H1 2020
Wilson Disease - Pipeline by LambdaGen Therapeutics, H1 2020
Wilson Disease - Pipeline by Nobelpharma Co Ltd, H1 2020
Wilson Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2020
Wilson Disease - Pipeline by Vivet Therapeutics SAS, H1 2020
Wilson Disease - Dormant Projects, H1 2020